FASL (CD178) is known for its role in triggering apoptosis, mostly in relation with immune cells but additional functions have been reported more recently, including those in bone development. Examination of postnatal FasL-deficient mice (gld) showed an increased bone deposition in adult mice when compared with wild types. However, a different phenotype was observed prenatally, when the gld bone was underdeveloped. The aim of the following investigation was to evaluate this indication for an growth-dependent bone phenotype of gld mice and to search for the 'switch point'. This study focused on the mandibular/alveolar bone as an important structure for tooth anchorage. In vivo micro-computed tomography (CT) analysis was performed at different stages during the first month (6, 12 and 24 days) of postnatal bone development. In 6-day-old gld mice, a decrease in bone volume/tissue volume (BV/TV), trabecular thickness and trabecular number was revealed. In contrast, the 12-day-old gld mice showed an increased BV/TV and trabecular thickness in the alveolar bone. The same observation applied for bone status in 24-day-old gld mice. Therefore, changes in the bone phenotype occurred between day 6 and 12 of the postnatal development. The switch point is likely related to the changing proportion of bone cells at these stages of development, when the number of osteocytes increases. Indeed, the immunohistochemical analysis of FASL localized this protein in osteoblasts, whereas osteocytes were mostly negative at examined stages. The impact of FASL particularly on osteoblasts would agree with an earlier in vivo observed effect of FASL deficiency on expression of Mmp2, typical for osteoblasts, in the gld mandibular/alveolar bone. Notably, an age-dependent bone phenotype was reported in Mmp2-deficient mice.

Department of Physiology University of Veterinary and Pharmaceutical Sciences Brno Czech Republic

Institute of Animal Physiology and Genetics Academy of Sciences Brno Czech Republic

Laboratory of Orofacial Pathologies Imaging and Biotherapies Université Paris Descartes Paris France

Zobrazit více v PubMed

Aghaloo TL, Chaichanasakul T, Bezouglaia O, et al. (2010) Osteogenic potential of mandibular vs. long‐bone marrow stromal cells. J Dent Res 89, 1293–1298. PubMed PMC

Blavier L, Delaisse JM (1995) Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 108, 3649–3659. PubMed

Florencio‐Silva R, Sasso GR, Sasso‐Cerri E, et al. (2015) Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int 2015, 421746. PubMed PMC

Gack S, Vallon R, Schmidt J, et al. (1995) Expression of interstitial collagenase during skeletal development of the mouse is restricted to osteoblast‐like cells and hypertrophic chondrocytes. Cell Growth Differ 6, 759–767. PubMed

Inoue K, Mikuni‐Takagaki Y, Oikawa K, et al. (2006) Crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism. J Biol Chem 281, 33814–33824. PubMed

Katavic V, Lukic IK, Kovacic N, et al. (2003) Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. J Immunol 170, 1540–1547. PubMed

Kawakami A, Eguchi K, Matsuoka N, et al. (1997) Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J Bone Miner Res 12, 1637–1646. PubMed

Kovacic N, Lukic IK, Grcevic D, et al. (2007) The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. J Immunol 178, 3379–3389. PubMed PMC

Krum SA, Miranda‐Carboni GA, Hauschka PV, et al. (2008) Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27, 535–545. PubMed PMC

Mosig RA, Martignetti JA (2013) Loss of MMP‐2 in murine osteoblasts upregulates osteopontin and bone sialoprotein expression in a circuit regulating bone homeostasis. Dis Model Mech 6, 397–403. PubMed PMC

Mosig RA, Dowling O, DiFeo A, et al. (2007) Loss of MMP‐2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet 16, 1113–1123. PubMed PMC

Nakamura T, Imai Y, Matsumoto T, et al. (2007) Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130, 811–823. PubMed

Ozeki N, Mogi M, Nakamura H, et al. (2002) Differential expression of the Fas‐Fas ligand system on cytokine‐induced apoptotic cell death in mouse osteoblastic cells. Arch Oral Biol 47, 511–517. PubMed

Park H, Jung YK, Park OJ, et al. (2005) Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 175, 7193–7201. PubMed

Sasaki M, Hongo H, Hasegawa T, et al. (2012) Morphological aspects of the biological function of the osteocytic lacunar canalicular system and of osteocyte‐derived factors. Oral Sci Int 9, 1–8.

Svandova E, Vesela B, Lesot H, et al. (2018) FasL modulates expression of Mmp2 in osteoblasts. Front Physiol 9, 1314. PubMed PMC

Wajant H (2002) The Fas signaling pathway: more than a paradigm. Science 296, 1635–1636. PubMed

Wajant H, Pfizenmaier K, Scheurich P (2003) Non‐apoptotic Fas signaling. Cytokine Growth Factor Rev 14, 53–66. PubMed

Wang L, Liu S, Zhao Y, et al. (2015) Osteoblast‐induced osteoclast apoptosis by FAS ligand/FAS pathway is required for maintenance of bone mass. Cell Death Differ 22, 1654–1664. PubMed PMC

Expression of osteogenic factors in FasL-deficient calvarial cells

FasL is a catabolic factor in alveolar bone homeostasis

Making the head: Caspases in life and death

Impact of FasL Stimulation on Sclerostin Expression and Osteogenic Profile in IDG-SW3 Osteocytes

FasL Is Required for Osseous Healing in Extraction Sockets in Mice